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Abstract
Introduction There is growing evidence that heritable genetic
variation modulates metastatic efficiency. Our previous work
using a mouse mammary tumor model has shown that
metastatic efficiency is modulated by the GTPase-activating
protein encoded by Sipa1  ('signal-induced proliferation-
associated gene 1'). The aim of this study was to determine
whether single nucleotide polymorphisms (SNPs) within the
human SIPA1 gene are associated with metastasis and other
disease characteristics in breast cancer.
Method The study population (n = 300) consisted of randomly
selected non-Hispanic Caucasian breast cancer patients
identified from a larger population-based series. Genomic
DNA was extracted from peripheral leukocytes. Three
previously described SNPs within SIPA1  (one within the
promoter [-313G>A] and two exonic [545C>T and
2760G>A]) were characterized using SNP-specific PCR.
Results The variant 2760G>A and the -313G>A allele were
associated with lymph node involvement (P = 0.0062 and P =
0.0083, respectively), and the variant 545C>T was associated
with estrogen receptor negative tumors (P = 0.0012) and with
progesterone negative tumors (P = 0.0339). Associations were
identified between haplotypes defined by the three SNPs and
disease progression. Haplotype 3 defined by variants -313G>A
and 2760G>A was associated with positive lymph node
involvement (P = 0.0051), and haplotype 4 defined by variant
545C>T was associated with estrogen receptor and
progesterone receptor negative status (P = 0.0053 and P =
0.0199, respectively).
Conclusion Our findings imply that SIPA1  germline
polymorphisms are associated with aggressive disease
behavior in the cohort examined. If these results hold true in
other populations, then knowledge of SIPA1 SNP genotypes
could potentially enhance current staging protocols.
Introduction
Breast cancer is a major public health concern among West-
ern female populations. In 2004 breast cancer was the most
common form of malignancy diagnosed in females in the USA
and the second leading cause of cancer mortality in women
[1]. The great majority of these deaths are related to complica-
tions caused by metastatic disease, and in spite of therapeutic
advances metastatic breast cancer is currently incurable [2]. It
has been estimated that 24–30% of women with node-nega-
tive disease and at least 50–60% of those with node-positive
disease at diagnosis will relapse [3]. Furthermore, approxi-
mately 6–10% of breast cancer patients present with clinical
evidence of metastasis, and the median survival of those with
metastatic disease is estimated to be 2–4 years [3].
The impact of metastatic disease on prognosis underscores
the importance of improving upon currently available means of
diagnosing and treating advanced breast cancer. One poten-
tially powerful approach would be to identify early those
patients who are at high risk for disseminated disease and
then administer tailored treatment to reduce or eliminate the
emergence of secondary lesions. As our knowledge of both
the genetic and molecular mechanisms underpinning metasta-
sis improves, it is becoming apparent that use of simple, relia-
CI = confidence interval; D' = Lewontin's D prime; ER = estrogen receptor; NCBI = National Center for Biotechnology Information; OR = odds ratio; 
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ble and robust assays that rely upon stable, constitutional
fingerprints, including germline DNA polymorphisms, may pro-
vide an alternative means of identifying patients at risk for
advanced disease. Recent studies have demonstrated that
low penetrance germline polymorphisms influence overall sus-
ceptibility to breast cancer (for review, see the report by Houl-
ston and Peto [4]) as well as the likelihood of tumor
progression and/or recurrence (for review, see the report by
Foulkes and coworkers [5]). Probably the best documented
genes with respect to the latter are BRCA1 and BRCA2, with
specific germline mutations being demonstrated to be associ-
ated with various indicators of poor outcome [6-9].
Previously, our laboratory provided evidence that the host
genetic background upon which a tumor arises can signifi-
cantly alter metastatic efficiency. This was demonstrated by a
breeding scheme in which the highly metastatic polyoma mid-
dle T transgenic mouse mammary tumor model was bred to a
variety of inbred strains and the metastatic capacity of the
tumors in each of the F1 hybrid populations determined [10].
Wide variations in metastatic efficiency for each of the differ-
ent F1  progeny were observed following mammary tumor
development [10], and because all of the tumors were induced
by the same transgenic event – namely the activation of the
polyoma middle T antigen [11] – it was concluded that the
observed difference in metastatic efficiency in F1 progeny was
a consequence of germline genetic variation between each of
the different inbred strains.
Quantitative trait mapping experiments revealed the presence
of a metastasis efficiency modifier locus linked to the proximal
end of mouse chromosome 19 [12]. Subsequent evaluation of
this locus identified a gene called Sipa1 ('signal-induced pro-
liferation-associated gene 1'; also known as Spa1) as a likely
candidate for this modifier locus. Sequence analysis of Sipa1
revealed an alanine to threonine mutation in the PDZ domain
in mice with high metastatic potential (FVB strain, AKR strain)
when compared with low metastatic phenotype mice (NZB
strain, DBA strain) [13]. Computer modeling of the wild-type
and mutant forms of Sipa1 indicated that this mutation occurs
on the open face of an α-helix, and in vitro analysis demon-
strated that the polymorphism functionally impacts on protein-
protein interactions. Furthermore, these data indicated that the
metastatic capacity of mammary tumors in spontaneous
metastasis assays was significantly altered by modulation of
Sipa1  expression. Metastatic capacity was increased by
Sipa1 upregulation as a consequence of ectopic gene expres-
sion [13], and a decrease in metastasis was seen when Sipa1
expression was reduced by RNA interference utilizing Sipa1-
specific short-hairpin RNAs.
The aim of this study is to determine whether SIPA1 (MIM#
602180) plays a similar role in the modulation of metastatic
potential in human breast cancer populations. We hypothe-
sized that polymorphisms or haplotypes within key regulatory
or coding elements of the human gene encoding SIPA1,
located on chromosome 11q13.3, are positively correlated
with the presence of metastases in breast cancer patients. To
test this hypothesis, we designed a case-only association
study in which a number of single nucleotide polymorphisms
(SNPs) in SIPA1 were characterized in patients with meta-
static or nonmetastatic breast cancer.
Materials and methods
Recruitment of patients
This study was approved by the institutional review boards of
the US National Institutes of Health and the University of Cali-
fornia (Irvine, CA, USA). Written informed consent was
obtained from all patients. The patients included in this study
are a subgroup of 300 women with breast cancer selected
from a larger population-based population of incident breast
cancer patients. Breast cancer probands diagnosed between
1 March 1994 and 28 February 1995 were identified through
the population-based cancer registry of the Cancer Surveil-
lance Program of Orange County. Description of the Program
and details of data collection methods were reported previ-
ously [14]. The overall goal of the parent study was to provide
a means to identify a large fraction of the population that is at
genetically high risk for breast or ovarian cancer, and to deter-
mine the significance of inherited cancer-predisposing genes
as risk factors for cancer development in the population.
We report here data on 300 breast cancer patients (all non-
Hispanic white women) selected from among the patients
included in the parent study as follows: approximately 51% of
patients with regional or metastatic breast cancer (154
cases); and randomly selected patients with localized disease
(146 cases). Regional disease indicates direct extension of
the primary tumor to the skin, muscle, chest wall, lymph nodes,
or a combination of the above; metastatic disease indicates all
other forms of involvement beyond regional disease. Patho-
logic diagnoses were obtained at the time of initial presenta-
tion in all cases, and the methods used for data collection
were standardized. The protocol included initial contact with
patients' physician followed by a mail-based invitation and
description of the study. After patients had consented to par-
ticipate in the study, family history and epidemiologic risk fac-
tors were assessed by telephone interview. In addition, data
on tumor characteristics and stage at diagnosis were col-
lected from the cancer registry. These data were based on
pathology reports and medical records of the cancer patients.
Blood samples were collected from all cancer patients, DNA
was extracted from each sample, and aliquots were sent to the
NCI (IRB #HS-2004-3832).
Selection of single nucleotide polymorphisms
We characterized three SNPs within the regulatory or coding
regions of SIPA1. SNPs were chosen on the basis of their
genomic location from the NCBI SNP database [15]. One pol-
ymorphism, -313G>A (NCBI SNP designation rs931127) isAvailable online http://breast-cancer-research.com/content/8/2/R16
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located 313 base pairs upstream of the 5'-untranslated region
of SIPA1 and is considered to be within the promoter region
of the gene. The remaining two SNPs are located within cod-
ing regions, one within exon 1 (545C>T [F182S]; rs3741378)
and one within exon 12 (2760G>A [A920A]; rs746429).
Single nucleotide polymorphism genotyping
SIPA1 polymorphisms were characterized using SNP-specific
PCR. The PCR primers were designed using Vector NTI 9.0
software (Invitrogen, Carlsbad, CA, USA), in accordance with
parameters described elsewhere [16]. Each probe was
labeled with a reporter dye (either VIC® [a proprietary fluores-
cent dye produced by Applied Biosystems, Foster City, CA,
USA] or FAM [5-(&6)-carboxyfluorescein]) specific for wild-
type and variant alleles of each of three SIPA1 SNPs, respec-
tively. Sequences of PCR primers and fluorogenic probes are
given in Table 1.
Reaction mixtures consisted of 300 nmol/l of each oligonucle-
otide primer, 100 nmol/l fluorogenic probes, 8 ng template
DNA, and 2× TaqMan Universal PCR Master Mix (Applied Bio-
systems) in a total volume of 10 µl. The amplification reactions
were performed in a MJ Research DNA Engine thermocycler
(Bio-Rad, Hercules, CA, USA) with two initial hold steps
(50°C for 2 minutes, followed by 95°C for 10 minutes) and 40
cycles of a two-step PCR (92°C for 15 s, 60°C for 1 minute).
The fluorescence intensity of each sample was measured
post-PCR in an ABI Prism 7700 sequence detection system
(Applied Biosystems), and SIPA1 SNP genotypes were deter-
mined by the fluorescence ratio of the nucleotide-specific
fluorogenic probes.
Statistical analysis
We used Student's t test to compare means for continuous
variables and Wilcoxon's sum rank test to compare medians.
Variables that were not normally distributed such as tumor size
were log transformed. χ2 test or Fisher's exact tests were used
to test for differences between categorical variables and test-
ing for Hardy-Weinberg equilibrium. Unconditional logistic
regression adjusting for multivariate covariates such as age at
diagnosis was used to estimate the adjusted odds ratios
(ORs). Lewontin's D prime (D') and correlation coefficient (r2)
were calculated as two measures of linkage disequlibrium.
Using the E-M algorithm [17], we estimated frequencies of the
most common haplotypes (with a frequency >1%) in this pop-
ulation and we imputed expected haplotypes for each subject.
Haplotype specific ORs were calculated from unconditional
logistic regression adjusting for multivariate covariates. We
used likelihood ratio tests to calculate P values comparing a
model with haplotypes versus a model without. All P values
presented are two tailed and were considered to be statisti-
cally significant if they were below 0.05.
Results
Patient population
Descriptive data on breast cancer patients included in the
study are summarized in Table 2, in which the two case groups
are described (patients with localized disease [n = 146] and
cases patients regional and metastatic disease [n = 154]).
The data in Table 2 show that the group with localized disease
was about 4 years older than those with advanced disease at
diagnosis (mean age at diagnosis: 59.7 years versus 55.2
years; P = 0.0042). Those with localized disease had a smaller
Table 1
PCR primer and SNP-specific fluorogenic oligonucleotide probe sequences
SIPA1 polymorphism Sequencea
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mean tumor size (1.6 cm versus 3.1 cm; P < 0.0001). In addi-
tion, the group with localized disease had a higher frequency
of well differentiated tumors (P < 0.0001). No difference in the
distribution of estrogen receptor (ER)-positive tumors and a
marginal statistical significant difference in progesterone
receptor (PR)-positive tumor status were observed between
the two study groups. No statistically significant associations
were observed between stage of the disease and other epide-
miologic risk factors such as alcohol use, smoking, age at
menarche, menopause status, parity, estrogen use, and family
history of breast, ovarian, or prostate cancer among first-
degree relatives.
Analysis of SIPA1 single nucleotide polymorphism 
genotype frequencies
The allele frequencies for the three SNPs in all breast cancer
patients included in the study were 0.359 for SNP -313G>A,
0.556 for SNP 545C>T, and 0.144 for SNP 2760G>A. For
none of the SNPs did the distribution deviate from Hardy-
Weinberg equilibrium. All three SNPs were in pairwise linkage
disequlibrium, as indicated by the parameter D', with D' values
of 0.94 between rs931127 and rs3741378, 0.85 between
rs931127 and rs746429, and 0.86 between rs3741378 and
rs746429.
In a univariate analysis between the distribution of the geno-
types and tumor characteristics, we observed the following.
First, -313G>A SNP genotypes were significantly associated
with the presence of positive lymph nodes at diagnosis;
33.3% of those with GG genotype had positive lymph nodes
as compared with 52.7% among those with GA or AA geno-
type (P = 0.0139). Second, 545C>T was associated with ER-
negative tumors, with 15.3% of those with CC genotype being
ER negative as compared with 34.8% among those with CT
or TT genotype (P = 0.0006); it was also associated with PR-
negative tumors, with 27.8% of those with CC genotype being
PR negative as compared with 42.0% among those with CT
or TT genotype (P = 0.0350). This indicated that the presence
of the T allele is associated with a number of indicators of a
more aggressive disease process. Third, the frequency distri-
bution of genotypes for the 2760G>A SNP revealed a signifi-
cant association between the presence of the AA or GA
genotype and advanced disease and the presence of positive
lymph nodes at diagnosis. The combined frequency of
homozygote variant AA and heterozygote GA genotypes was
significantly higher in those individuals with nonlocalized,
advanced disease than in individuals in whom the tumor
remained confined to the breast (65.3% versus 50.4%; P =
0.0154). A similar pattern was observed with respect to lymph
Table 2
Participant characteristics by localized and regional/metastatic disease
Characteristic Localized (n = 148) Regional/metastatic (n = 152) P
Age at diagnosis <50 years 44 (30.1%) 57 (37.0%) 0.0042a
≥50 years 102 (69.9%) 97 (63.0%)
Mean age (years; mean ± SD) 59.7 ± 14.3 55.2 ± 12.6
Range (years) 33–91 25–87
ER status Positive 109 (74.7%) 105 (68.2%) 0.1741b
Negative 22 (15.0%) 33 (21.4%)
Unknown 15 (10.3%) 16 (10.4%)
PR status Positive 96 (65.7%) 87 (56.5%) 0.0489b
Negative 33 (22.7%) 451 (33.1%)
Unknown 17 (11.6%) 16 (10.4%)
Tumor size < 2 cm 102 (69.9%) 55 (35.7%) <0.0001c
≥ 2 cm 34 (27.4%) 84 (54.6%)
Unknown 4 (2.7%) 15 (9.7%)
Mean size (cm; mean ± SD) 1.6 ± 1.0 3.1 ± 2.7
Range (cm) 0.1–6.5 0.4–18.0
Grade Well to moderate 86 (58.9%) 46 (29.9%) <0.0001b
Poor 26 (17.8%) 79 (51.3%)
Unknown 34 (23.3%) 29 (18.8%)
Values are expressed as n (%), unless otherwise stated. aBased on a t-test. bBased on a Fisher's exact test excluding the missing values. cBased 
on a t-test on the logarithmic scale. ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation.Available online http://breast-cancer-research.com/content/8/2/R16
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node involvement, in which the combined frequency of
homozygote variants (AA) and heterozygotes (GA) was higher
in those individuals with metastasis in one or more axillary
lymph nodes than in those with no nodal involvement (64.5%
versus 50.4%; P = 0.0074). These findings indicate that the
variant A allele is associated with a more aggressive disease
process.
The genotype frequencies for each of the three SNPs in the
study population by tumor characteristics are presented in
Table 3. In addition, Table 3 shows the univariate and multivar-
iate-adjusted OR and 95% confidence interval (CI) of the
tumor characteristics according to the genotypes of the three
SNPs, assuming a dominant model. In the multivariable analy-
sis we included age at diagnosis in all models. Thus, for the -
313G>A SNP the multivariate OR of the presence of positive
lymph nodes was 2.15 (95% CI 1.14–4.06;P = 0.0083). This
implies that an individual with the GA or AA genotype was
2.15 times more likely to have positive lymph nodes than was
an individual with GG genotype. The multivariable OR of the -
545C>T allele and ER and PR status were 2.90 (95% CI
1.52–5.48; P = 0.0012) and 1.86 (95% CI 1.05–3.30;P =
0.0339), respectively. Similarly, for the -2760G>A SNP the
multivariate OR of the presence of positive lymph nodes was
2.05 (95% CI 1.23–3.44;P = 0.0062). This implies that an
individual with the GA or AA genotype was 2.05 times more
likely to have positive lymph nodes than was an individual with
the GG genotype.
Analysis of SIPA1 single nucleotide polymorphism 
haplotype frequencies
We investigated the association between haplotypes defined
by these three SNPs and the presence of positive lymph
nodes, and ER and PR status. There were a total of seven hap-
lotypes that were imputed from the data on 260 patients with
complete genotypes on all three SNPs. However, four of those
haplotypes accounted for more than 98% of the observations.
Table 4 summarizes the estimated frequencies of the pre-
dicted haplotypes, and Table 5 presents the haplotype-spe-
cific ORs of the association of haplotypes and the presence of
positive lymph nodes, and ER and PR status compared with
the most common haplotype (haplotype 1). Haplotypes with
allele frequency below 1% were included with the baseline in
our analysis. In the analysis of the presence of positive lymph
nodes and haplotypes, the haplotype specific OR for haplo-
type 3 was 2.20 (95% CI 1.27–3.81; P = 0.0051) compared
with haplotype 1. Thus, women with the estimated haplotype
3 were 2.20 times more likely to present with positive lymph
nodes than were women with haplotype 1. In the analysis of
ER status and haplotypes, the haplotype specific OR for hap-
Table 3
Genotype distribution by tumor characteristics
SNP genotype Disease characteristic 
(n [%])
Odds ratios 95% CI P
Crude Adjusteda
-313G>A (rs931127; negative/positive nodes)
GG 36 (27.5)/18 (14.5) 1.00 1.00
GA 58 (44.3)/60 (48.4) 2.23 2.15 1.14–4.06 0.0083
AA 34 (28.2)/46 (37.1)
545C>T (rs3741378; ER positive/ER negative)
CC 166 (78.7)/30 (55.6) 1.00 1.00
CT 39 (18.5)/22 (40.7) 2.95 2.90 1.52–5.48 0.0012
TT 6 (2.8)/2 (2.0)
545C>T (rs3741378; PR positive/PR negative)
CC 140 (77.8)/54 (65.1) 1.00 1.00
CT 35 (19.4)/26 (31.3) 1.88 1.86 1.05–3.30 0.0339
TT 5 (2.8)/3 (3.6)
2760G>A (rs746429; negative/positive nodes)
GG 64 (49.6)/41 (32.5) 1.00 1.00
GA 46 (35.7)/65 (51.6) 2.04 2.05 1.23–3.44 0.0062
AA 19 (14.7)/20 (20.0)
aAdjusted analysis models include age at diagnosis. CI confidence interval; ER, estrogen receptor; progesterone receptor.Breast Cancer Research    Vol 8 No 2    Crawford et al.
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lotype 4 was 2.85 (95% CI 1.36–5.94; P = 0.0053) com-
pared with haplotype 1. Thus, women with the estimated
haplotype 4 were 2.85 times more likely to present with an ER-
negative tumor than were women with haplotype 1. In the anal-
ysis of PR status and haplotypes, the haplotype-specific OR
for haplotype 4 was 2.16 (95% CI 1.13–4.12; P = 0.0199)
compared with haplotype 1. Thus, women with the estimated
haplotype 4 were 2.16 times more likely to present with a PR-
negative tumor than were women with haplotype 1.
Discussion
In this preliminary study we observed strong associations
between the three SIPA1 SNPs and indicators of aggressive
breast cancer in this population. Specifically, we report a
number of particularly interesting findings regarding nodal sta-
tus at the time of diagnosis and tumor sex hormone receptor
status; these findings suggest that SIPA1 germline variation
contributes to metastatic potential in breast cancer. With
regard to lymph node involvement, the variant -313G>A and
2760G>A alleles were strongly associated with axillary node
involvement at the time of diagnosis on univariate analysis.
Indeed, the apparent effect of these SNPs on the frequency of
metastasis that was evident upon univariate analysis was com-
plemented by the outcome of multivariate and haplotype fre-
quency estimation. Multivariate analysis of genotype
frequencies showed that possession of either of the -313G>A
or 2760G>A variant alleles was associated with a significantly
increased likelihood of nodal involvement. Similarly, haplotype
analyses demonstrated that the haplotype consisting of the
wild-type allele of 545C>T and the variant alleles of the two
other studied SNPs (haplotype 3; Table 5) is associated with
nodal involvement at the time of diagnosis. This apparent asso-
ciation with nodal involvement at the time of diagnosis is par-
ticularly interesting given that there was no evidence of
association of SIPA1 genotype status and tumor size. It was
previously demonstrated that a linear relation exists between
tumor diameter and the percentage of cases with positive
lymph node involvement [18]. One would therefore expect
similar associations with tumor size, given the apparent rela-
tionship with nodal status at diagnosis. However, this was not
the case in the present study, which may well be a conse-
quence of inadequate statistical power to detect such an
association. Alternatively, SIPA1  polymorphism might facili-
tate nodal metastasis independent of tumor size. Whichever is
the case, further analysis of the significance of these polymor-
phisms in different populations is required to clarify the situa-
tion.
SIPA1 polymorphisms in this population were also associated
with other features of tumors with aggressive behavior. Posi-
tive sex hormone receptor status correlates with favorable
prognostic features, including a lower rate of cell proliferation
and histological evidence of tumor differentiation [19]. The
545C>T variant allele was associated with ER-negative and
PR-negative tumors in this cohort. In addition, haplotype 4,
which is defined by the variant allele 545C>T, is strongly asso-
ciated with ER and PR tumor status (Table 5). This again high-
lights the deleterious effect that SIPA1 germline variation has
on prognosis in primary breast carcinoma and implies that var-
iant forms of this gene are associated with more aggressive
disease forms.
The importance of these data is heightened when one consid-
ers the outcome of our linkage and functional studies of Sipa1
in a murine population [12,13,20], coupled with consideration
of the known physiologic functions of SIPA1. Traditional
dogma has stated that cancerous cells gain the ability to
metastasize as a consequence of somatic mutation (for exam-
ple, through loss of heterozygosity or epigenetic events). How-
ever, it has become increasingly accepted that hereditary
factors influence all stages of tumor pathogenesis in appar-
ently sporadic cancers. These heritable defects will be of low
penetrance, but hypothetically they could affect any part of the
neoplastic cascade, including modulation of metastatic effi-
ciency. Evaluation of quantitative trait loci in inbred mouse
models has proven a particularly powerful means of studying
the effects of this type of genetic variation. The present study
is an additional example of how mouse quantitative trait locus
Table 4
Estimated frequencies of predicted haplotypes
Haplotype -313G>A (rs931127) 545C>T (rs3741378) 2760G>A (rs746429) Estimated frequency (%)
1G C G 4 2 . 1
2A C G 8 . 0
3A C A 3 4 .  6
4A T G 1 3 .  5
5a GCA 0 . 9
5a GTG 0 . 5
5a ATA 0 . 3
Haplotypes frequencies were estimated from the 260 samples with complete genotype data on all three polymorphisms. aHaplotypes with an 
estimated frequency below 1% were pooled for the purposes of analysis.Available online http://breast-cancer-research.com/content/8/2/R16
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data, when used in an appropriate manner, can help to unravel
the complexities of hereditary influences in sporadic human
cancer [21].
Although the specific mechanism by which SIPA1 modulates
metastatic efficiency is currently unclear, it is worthwhile to
speculate on how observations of SIPA1 functionality in mice
and humans may relate to the process of tumor progression
and characterization. Specifically, tumor development in a
background of germline-encoded SIPA1  dysfunction may
enhance the ability of tumor cells to escape the primary lesion
through alteration in cell morphology/polarity and/or by weak-
ening the strength of intercellular contacts. This argument
gains further potency when one considers the negative regu-
latory effect of SIPA1 on Rap1, and that Rap1 has been impli-
cated in the maintenance of epithelial polarization [22] as well
as in the maintenance of intercellular adherens junctions [23].
Further studies will be required to confirm whether this is the
case.
SIPA1 has been shown to have GTPase activity that is spe-
cific for Rap1 and Rap2, both of which are members of the
Ras family of GTPases, and are involved in regulating cell pro-
liferation, differentiation, and adhesion [24]. Indeed, SIPA1
appears to play a prominent role in regulating cell adhesion,
and transient expression of this gene in HeLa cells induces
cellular rounding up and detachment from the culture surface
[25]. It appears to act by modulating a number of cellular adhe-
sion molecules, for example β1-integrin, and thus regulates the
interactions between these molecules and other cellular and
extracellular matrix proteins involved in the process of adhe-
sion [26-28]. It has been hypothesized that SIPA1 negatively
regulates integrin-mediated cell adhesion via Rap1 GAP activ-
ity [27]. Specifically, SIPA1 interacts with the cytoskeletal-
anchoring protein AF6 through a common protein-protein
interaction motif known as a 'PDZ domain' [27].
In addition to the effects on intercellular adhesion, disruption
of SIPA1 has been shown to have potent effects on cellular
proliferation. For example, SIPA1-deficient mice develop a
spectrum of symptoms resembling those seen in human mye-
lodysplastic and myeloproliferative disorders [29,30]. This is
especially noteworthy because metastatic cells must be able
to proliferate effectively at a distant site in what must be con-
sidered a foreign microenvironment, if they are to become a
clinically relevant metastatic lesion. When all this evidence is
considered, we argue that functional data from both mouse
and human studies strongly support the findings of the present
case-only study, in which we demonstrate that germline poly-
morphisms and haplotypes of SIPA1  are associated with
enhanced metastatic efficiency in primary breast carcinoma.
However, further experiments will be required to confirm the
role of SIPA1 germline variation in modulating tumor progres-
sion efficiency, the most obvious of which is to replicate the
associations seen here in other populations. It is also vital to
resequence various elements of the SIPA1 gene to attempt to
identify novel polymorphisms, the most critical of which is that
encoding the PDZ protein-protein interaction domain – a
region that is critical to SIPA1 functionality [27]. This endeavor
is especially important given that the exon 12 2760G>A SNP
– a noncoding, synonymous polymorphism – is strongly asso-
ciated with aggressive disease in this study. This may well be
a reflection of the physical proximity of this SNP to the other
polymorphisms characterized in the study, which could have a
more plausible effect on SIPA1 functionality. This hypothesis
is somewhat supported when one considers that a haplotype
containing the 2760G>A variant allele is associated with more
aggressive disease at diagnosis, as measured by positive
lymph node involvement. Conversely, it may well be that the
2760G>A SNP is in linkage disequilibrium with a nearby yet
uncharacterized SNP with a more obvious functional effect.
Indeed, one could postulate that the associations observed in
the present study are in fact a consequence of another gene
in linkage disequilibrium with SIPA1, because the functional
significance (if any) of each of the polymorphisms has not
been assessed. However, we argue that this is unlikely
because we investigated genes in the chromosomal regions
surrounding Sipa1 in the mouse and found no data supporting
the hypothesis that surrounding genes are involved in modu-
Table 5
Haplotype specific odds ratios adjusted for age and association with tumor characteristics
Haplotypea Positive nodes ER status PR status
OR (95% CI) P OR (95% CI) P OR (95% CI) P
1 1.00 1.00 1.00
2 1.14 (0.52–2.51) 0.7410 0.93 (0.34–2.60) 0.8961 0.99 (0.42–2.33) 0.9828
3 2.20 (1.27–3.81) 0.0051* 0.62 (0.30–1.29) 0.2005 1.50 (0.82–2.77) 0.1915
4 1.00 (0.54–1.86) 0.9940 2.85 (1.36–5.94) 0.0053* 2.16 (1.13–4.12 0.0199*
aHaplotypes with an estimated frequency under 1% were pooled within the baseline for the purposes of analysis. *Statistically significant 
comparisons of haplotype frequencies.Breast Cancer Research    Vol 8 No 2    Crawford et al.
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lating metastatic efficiency [13]. This, in combination with
observations relating to Sipa1 functionality in the mouse and
the fact that human haplotype blocks are probably significantly
smaller than in inbred mice, leads to the conclusion that the
observed associations are a result of SIPA1 polymorphism.
The implications of this work are potentially far reaching in that
it may well prove possible to assess metastatic potential
through genotyping polymorphisms in germline DNA. The abil-
ity to evaluate the risk for metastatic disease from readily avail-
able tissues such as blood could be a powerful means to
augment currently available means of assessing prognosis in
breast cancer. However, we do acknowledge that the effect of
germline SIPA1 variation in isolation is probably too low to
allow for the development of an assay that would possess suf-
ficient sensitivity and specificity to determine metastatic pro-
pensity accurately. However, it is plausible that a panel of
polymorphisms derived from a number of metastasis 'suscep-
tibility' genes would possess the power and accuracy to ena-
ble the development of a clinically relevant prognostic assay,
which will necessitate the identification of further metastasis
efficiency modifier genes.
Conclusion
Our results imply that SIPA1  germline polymorphisms are
associated with aggressive disease behavior in the present
cohort. If the results of this study hold true in other popula-
tions, then the potential for this to have a positive impact on
current breast cancer staging and treatment protocols may be
great. For example, staging of primary breast cancer in cases
in which there is no palpable evidence of nodal metastasis typ-
ically requires axillary dissection to assess nodal status. How-
ever, controversy exists as to the actual benefit of nodal
sampling in those patients with small tumors because of the
morbidity frequently associated with this procedure. For exam-
ple, the incidence of axillary node relapse in patients with
stage T1a tumors (tumor >0.1 cm but not >0.5 cm in greatest
dimension) treated without axillary dissection was 2% [31]. It
is plausible that analysis of SIPA1 polymorphisms could be
used as an additional element of the staging process that
might allow axillary node-negative patients with small primary
tumors (for example, T1-2 N0) to be classed as being at
increased risk for development of metastasis. In turn, this
could then become a powerful influence on whether to initiate
adjuvant therapy in patients who would not currently be con-
sidered for this type of treatment.
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